STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech
2023年12月29日 - 10:00PM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ:
SSKN), a medical technology company dedicated to developing,
commercializing and marketing innovative products for the treatment
of dermatologic conditions, today announced the expansion of a
direct distribution agreement with Kosmo Meditech (“Kosmo”), which
is now assigned to Kosmo's corporate parent, Cutech, Inc.,
effective as of January 1, 2024, for a combination of direct
capital sales and direct recurring revenue sales in Korea.
The key highlights of this amendment, which
reinforce STRATA's commitment to innovation and customer
satisfaction, include:
- Extended term through December 31,
2026, ensuring a prolonged and stable partnership
- Established defined annual and
quarterly performance-based purchase requirements, including STRATA
becoming sole provider of gas and consumables, securing a
consistent demand for STRATA’s products, providing a reliable
forecast for production and inventory management, and ensuring
stronger top-line revenue
“This agreement not only signifies the strength
and growth of the partnership between STRATA and Kosmo but also
reinforces STRATA's dedication to upholding the highest standards
in product and service offerings for dermatological treatments
worldwide,” stated Dr. Dolev Rafaeli, President and Chief Executive
Officer of STRATA. “Korea continues to present a significant
opportunity for us, leveraging Kosmo’s extensive in-country
distribution network. This ongoing collaboration allows us to
provide our customers with innovative therapeutic solutions while
ensuring a framework for sustainable growth and market
leadership.”
About Kosmo MeditechKosmo Meditech is a Korean
distributor of medical devices in Dermatology and other medical
markets. Kosmo Meditech has been a distributor of the XTRAC®
excimer laser in partnership with STRATA Skin Sciences (and its
predecessor) for over 16 years. The Kosmo platform in combination
with the know-how generated by STRATA in the US will enable an
efficient deployment of the business model into existing and new
Dermatology clinics.
The Korean Dermatology clinic market comprises
1,800 physicians. XTRAC has been sold and is used by over 250
hospital and private practice clinics.
Korea’s Vitiligo and Psoriasis patient
population is approximately 1 million. The treatment by 308nm
Excimer is covered by the national health insurance with
reimbursement rates of $15 to $50 per procedure.
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company dedicated to developing,
commercializing and marketing innovative products for the in-office
treatment of various dermatologic conditions such as psoriasis,
vitiligo, and acne. Its products include the XTRAC® excimer laser,
VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership Program.
STRATA’s popular partnership approach includes a fee per treatment
cost structure versus an equipment purchase, installation and use
of the device, on-site training for practice personnel, service and
maintenance of the equipment, dedicated account and customer
service associates, and co-op advertising support to help raise
awareness and promote the program within the practice.
Safe HarborThis press release includes
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not
limited to the Company’s plans, objectives, expectations and
intentions and may contain words such as “will,” “may,” “seeks,”
and “expects,” that suggest future events or trends. These
statements, the Company’s ability to launch and sell an acne
treatment device and to integrate that device into its product
offerings, the Company’s ability to develop, launch and sell
products recently acquired or to be developed in the future, the
Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and
www.strataskinsciences.com.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 8 2024 まで 9 2024
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 9 2023 まで 9 2024